Loading stock data…
Annexon (ANNX)
$4.87+0.03 (+0.62%)
Pre-Market$4.88+0.01 (+0.21%)· Last close Sep 4
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Annexon, Inc. in the Healthcare sector is trading at $4.87 with a market capitalization of $738M. Wall Street consensus targets $15.29 (7 analysts), implying a +213.9% move over the next 12 months. The stock is currently 32% below its 52-week high of $7.18, remaining 9.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +213.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.05M↑ | -$50.26M↑ | -$57.02M↓ | -$51.73M↑ | -$57.41M |
| Net Income | -$44.14M↑ | -$48.26M↑ | -$54.92M↓ | -$49.16M↑ | -$54.36M |
Peer Comparison
JNJUNHPFE
Fundamentals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$738.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-96.06%
Volume
Today's trading volume
1.23M
Recent News
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders
In August 2026, Annexon reported a higher second-quarter net loss of US$55.35 million but a lower year-to-date loss of US$99.49 million, while updating investors on its ongoing Phase 3 ARCHER II trial and new open-label extension study for vonaprument in geographic atrophy. A distinctive aspect of this update is Annexon’s dual primary endpoint design at Months 15 and 24 for ARCHER II, paired with vonaprument’s FDA Fast Track and EMA PRIME designations, which together clarify a globally...
Annexon (ANNX) Q2 2026 Earnings Call Transcript
GBS and geographic atrophy programs advance toward 2026-2027 regulatory submissions.
Annexon (ANNX), What Is Behind Its Latest Update?
Annexon (ANNX) stock was in focus after the company updated investors on its late stage pipeline, highlighting a dual primary endpoint for the Phase 3 ARCHER II trial and new Guillain Barré syndrome data. See our latest analysis for Annexon. Against this backdrop of clinical updates and financing activity, Annexon’s share price has eased in the near term, with a 30 day share price return of 5.33% and a 90 day share price return of 0.74%. In contrast, the year to date share price return of...
Annexon, Inc. Q2 2026 Earnings Call Summary
Moby summary of Annexon, Inc.'s Q2 2026 earnings call
Annexon Q2 Earnings Call Highlights
Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the